Walmart shares slide as U.S. sales hit by falling drug prices

Walmart’s second-quarter report offered a rare blemish in its otherwise steady growth narrative. Comparable U.S. sales rose just 2.6% — the retailer’s slowest pace in over six years — sending shares lower. The culprit, according to the company, was falling drug prices, which dampened the value of sales at the pharmacy counter.

Pharmacy operations are both a sales driver and a traffic magnet for big-box retailers. When drug prices deflate, the dollar amount per transaction shrinks even if unit volume holds steady, creating a mechanical drag on revenue growth. The result raises an important question for investors: is this isolated to Walmart’s pharmacy aisle, or a signal of broader pricing pressures across the retail healthcare segment?

The key focus moving forward will be the trajectory of drug-price trends and how Walmart manages margins in this category. Whether the slowdown persists in the second half of the year — and whether pharmacy-driven deflation shows up in competitors' results — will help determine if this quarter was an anomaly or the start of a new pattern.